1. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
- Author
-
Theodora A. Koulis, Susan P. Lees-Miller, Anthony M. Magliocco, Robyn Banerjee, Elizabeth N. Kornaga, Tien Phan, Prafull Ghatage, and Corinne M. Doll
- Subjects
0301 basic medicine ,medicine.medical_specialty ,PTHgb, pre-treatment hemoglobin ,Leukocytosis ,Anemia ,Plt, platelet ,NLR, neutrophil-to-lymphocyte ratio ,R895-920 ,LDR, low dose rate ,AOTHgb, average on treatment hemoglobin ,Gastroenterology ,Article ,OS, overall survival ,Medical physics. Medical radiology. Nuclear medicine ,HDR, high dose rate ,03 medical and health sciences ,0302 clinical medicine ,PA, paraortic ,Internal medicine ,EBRT, external beam radiotherapy ,medicine ,Radiology, Nuclear Medicine and imaging ,Neutrophil to lymphocyte ratio ,RC254-282 ,Thrombocytosis ,Cervical cancer ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Retrospective cohort study ,Prognosis ,medicine.disease ,CRT, chemoradiotherapy ,Surgery ,030104 developmental biology ,BT, brachytherapy ,Oncology ,030220 oncology & carcinogenesis ,Hgb, hemoglobin ,PFS, progression free survival ,Cohort ,medicine.symptom ,business ,Chemoradiotherapy ,WBC, white blood cell - Abstract
Introduction: Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematologic parameters have emerged as potential indicators of worse outcome in this patient group. In a cohort of cervical cancer patients treated with chemoradiotherapy (CRT) and brachytherapy, we report on the prognostic significance of hematologic parameters including anemia, leukocytosis, neutrophil to lymphocyte ratio (NLR), and thrombocytosis, the effect of combining anemia with other hematologic parameters, and the effect of changes in hemoglobin levels during treatment. Materials and methods: Two-hundred fifty-seven cervical cancer patients were retrospectively identified from a single cancer institution’s database. Hematologic parameters were categorized as: anemia (hemoglobin ≤115 g/L), leukocytosis (white blood cell count >10 × 109/L), thrombocytosis (platelets >400 × 109/L), and NLR (ratio >5). The association between clinical factors and hematologic parameters on progression-free survival (PFS) and overall survival (OS) were assessed at 5 years. Results: At 5 years, both pre-treatment anemia (PFS: 60% vs 34%, p
- Published
- 2017
- Full Text
- View/download PDF